Anzeige
Mehr »
Login
Mittwoch, 15.01.2025 Börsentäglich über 12.000 News von 681 internationalen Medien
Löst diese riesige Entdeckung die Kupferkrise der KI? So ändert sich die Rechnung durch diesen Explorer!!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A1KCL7 | ISIN: US3765491010 | Ticker-Symbol: 3L4
Frankfurt
15.01.25
08:03 Uhr
10,110 Euro
-0,010
-0,10 %
Branche
Immobilien
Aktienmarkt
Sonstige
1-Jahres-Chart
GLADSTONE LAND CORPORATION Chart 1 Jahr
5-Tage-Chart
GLADSTONE LAND CORPORATION 5-Tage-Chart
RealtimeGeldBriefZeit
10,16010,36013:37
10,16010,36013:37
ACCESSWIRE
453 Leser
Artikel bewerten:
(2)

Gladstone Land Corporation: Gladstone Land Announces Increase in Monthly Cash Distributions for July, August and September 2024 and Earnings Release and Conference Call Dates for the Second Quarter Ended June 30, 2024

Finanznachrichten News

MCLEAN, VA / ACCESSWIRE / July 9, 2024 / Gladstone Land Corporation (NASDAQ:LAND) ("Gladstone Land" or the "Company") announced today that its board of directors declared the following cash distributions for each of July, August and September 2024.

Monthly Cash Distributions:

Common Stock: $0.0467 per share of common stock for each of July, August and September 2024, payable per the table below:

Summary of Common Stock Cash Distributions

Record Date

Payment Date

Amount

July 22

July 31

$ 0.0467

August 21

August 30

0.0467

September 20

September 30

0.0467

Total for the Quarter:

$ 0.1401

The Company has paid 137 consecutive monthly cash distributions on its common stock since its initial public offering in January 2013 and has increased its common stock distributions 35 times over the prior 38 quarters. The Company offers a dividend reinvestment plan (the "DRIP") to its common stockholders. For more information regarding the DRIP, please visit www.GladstoneLand.com.

Series B Preferred Stock (Nasdaq: LANDO): $0.125 per share of Series B Preferred Stock for each of July, August and September 2024, payable per the table below:

Summary of Series B Preferred Stock Cash Distributions

Record Date

Payment Date

Amount

July 22

July 31

$ 0.125

August 21

August 30

0.125

September 20

September 30

0.125

Total for the Quarter:

$ 0.375

The Company has not skipped, reduced, or deferred a monthly Series B Preferred Stock distribution to date.

Series C Preferred Stock (Nasdaq: LANDP): $0.125 per share of Series C Preferred Stock for each of July, August and September 2024, payable per the table below:

Summary of Series C Preferred Stock Cash Distributions

Record Date

Payment Date

Amount

July 22

July 31

$ 0.125

August 21

August 30

0.125

September 20

September 30

0.125

Total for the Quarter:

$ 0.375

The Company has not skipped, reduced, or deferred a monthly Series C Preferred Stock distribution to date.

Series D Preferred Stock (Nasdaq: LANDM): $0.104167 per share of Series D Preferred Stock for each of July, August and September 2024, payable per the table below:

Summary of Series D Preferred Stock Cash Distributions

Record Date

Payment Date

Amount

July 22

July 31

$ 0.104167

August 21

August 30

0.104167

September 20

September 30

0.104167

Total for the Quarter:

$ 0.312501

The Company has not skipped, reduced, or deferred a monthly Series D Preferred Stock distribution to date.

Series E Preferred Stock (Unlisted): $0.104167 per share of Series E Preferred Stock for each of July, August and September 2024, payable per the table below:

Summary of Series E Preferred Stock Cash Distributions

Record Date

Payment Date

Amount

July 22

July 31

$ 0.104167

August 21

August 30

0.104167

September 20

September 30

0.104167

Total for the Quarter:

$ 0.312501

The Company has not skipped, reduced, or deferred a monthly Series E Preferred Stock distribution to date.

Earnings Announcement:

The Company also announced today that it plans to report earnings for its second quarter ended June 30, 2024, after the stock market closes on Thursday, August 8, 2024. The Company will hold a conference call on Friday, August 9, 2024, at 8:30 a.m. Eastern Time to discuss its earnings results. Please call (877) 424-3437 to join the conference call. An operator will monitor the call and set a queue for questions.

A conference call replay will be available after the call and will be accessible through August 16, 2024. To hear the replay, please dial (877) 660-6853 and use playback conference number 13746758.

The live audio broadcast of the Company's conference call will also be available online at www.GladstoneLand.com.

About Gladstone Land:

Gladstone Land is a publicly-traded real estate investment trust that invests in farmland located in major agricultural markets in the U.S., which it leases to farmers. The Company, which reports the aggregate fair value of its farmland holdings on a quarterly basis, currently owns 168 farms, comprised of approximately 112,000 acres in 15 different states and over 49,000 acre-feet of banked water in California, valued at a total of approximately $1.5 billion. Additional information can be found at www.GladstoneLand.com.

For stockholder information on Gladstone Land, call (703) 287-5893. For Investor Relations inquiries related to any of the monthly dividend-paying Gladstone funds, please visit www.GladstoneCompanies.com.

For further information: Gladstone Land Corporation, (703) 287-5893

SOURCE: Gladstone Land Corporation



View the original press release on accesswire.com

© 2024 ACCESSWIRE
Gewinner im Megamarkt
Biotechnologie ist eine der bedeutendsten Zukunftstechnologien unserer Zeit. Zahlreiche Biotechnologie- und Pharmakonzerne haben sich unter anderem dem Kampf gegen Tumorerkrankungen verschrieben. Der weltweite Markt für Krebsmedikamente verzeichnet ein stetiges Wachstum. Für das Jahr 2025 wird ein Umsatz von etwa 190,3 Milliarden Euro prognostiziert, mit einer erwarteten jährlichen Wachstumsrate von 6,42% bis 2029, was zu einem geschätzten Marktvolumen von 244,1 Milliarden Euro führen würde.

Wir haben 3 aussichtsreiche Biotechnologieaktien mit Schwerpunkt Erforschung und Entwicklung von Wirkstoffen gegen Tumorerkrankungen ausfindig gemacht, die in den kommenden Monaten und Jahren erhebliches Aufwärtspotenzial versprechen und Vervielfachungspotenzial besitzen.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien durchstarten und zu Ihrem Börsenerfolg in 2025 beitragen könnten!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.